THE LACK OF BIOLOGICAL RELEVANCE OF THE OFFICIAL IN VITRO DISSOLUTION METHODOLOGY FOR THE IMMEDIATE RELEASE SOLID ORAL DOSAGE FORMS OF KETOCONAZOLE

Similar documents
Biowaiver Study on Prednisolone Tablets 5 mg in Three Different Brands. Marketed in Sudan. Safaa Mohamed *, Tilal Elsaman

Biorelevant dissolution of candesartan cilexetil

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

PQRI Workshop Bethesda 2012

Fed and Fasted Conditions Dissolution Studies

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

A TURBIDIMETRIC METHOD FOR THE ASSAY OF MELOXICAM USING MOLYBDOPHOSPHORIC ACID

THE OPTIMIZATION OF PROLONGED RELEASE MATRIX TABLETS WITH BETAHISTINE DIHYDROCHLORIDE - Part I

Impact of Sample Preparation on Dissolution Testing: Drug Binding and Extractable Impurities and Their Effect on Dissolution Data

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

The BCS: Where Do We Go from Here?

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

This revision also necessitates a change in the table numbering in the test for Organic Impurities.

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3

Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media

Global College of Pharmacy, Kahnpur Khui, Tehsil Anandpur Sahib, Distt.- Ropar, Punjab, India

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

Formulation and evaluation of sublingual tablets of lisinopril

Bioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

ENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE

IMPAIRMENT OF THE IN VITRO RELEASE OF CARBAMAZEPINE FROM TABLETS

Patel B et al. IRJP 1 (1)

contents of the monograph in effect today. Please refer to the current edition of the USP NF for official text.

1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012

Define the terms biopharmaceutics and bioavailability.

A STUDY ON SUITABILITY OF NIMESULIDE-BETACYCLODEXTRIN COMPLEX IN ORAL AND TOPICAL DOSAGE FORMS

Similar or Not? Comparison of Dissolution Profiles of Different Hydroxypropylmethyl Cellulose (HPMC) Capsules

FACTORIAL STUDIES ON THE EFFECTS OF HYDROXY PROPYL β- CYCLODEXTRIN AND POLOXAMER 407 ON THE SOLUBILITY AND DISSOLUTION RATE OF BCS CLASS II DRUGS

FORMULATION AND CHARACTERIZATION OF TELMISATAN SOLID DISPERSIONS

Change to read: BRIEFING

BCS: Dissolution Testing as a Surrogate for BE Studies

A FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS

COMPARISON OF QUALITY CONTROL OF TWO DIFFERENT B-COMPLEX TABLETS AND THEIR LEGISLATIVE ISSUES ON THE ALBANIAN PHARMACEUTICAL MARKET

Metformin IR tablets: partial in vitro dissolution profiles differences do not preclude in vivo bioequivalence

ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF NIMESULIDE BY CYCLODEXTRINS, POLOXAMER AND PVP

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Folic Acid in Human Nutrition

World Journal of Pharmaceutical Research SJIF Impact Factor 5.990

2- Minimum toxic concentration (MTC): The drug concentration needed to just produce a toxic effect.

HPLC to UHPLC Transfer of USP Method for Amlodipine Besylate Using the Agilent 1290 Infinity II LC

Application of IVIVCs in Formulation Development Douglas F Smith

Biopharmaceutics Dosage form factors influencing bioavailability Lec:5

Research Article Derivative Spectrophotometric Method for Estimation of Metformin Hydrochloride in Bulk Drug and Dosage Form

PK-UK Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability. Bath, November 2014

FORMULATION AND EVALUATION OF VALSARTAN TABLETS EMPLOYING CYCLODEXTRIN-POLOXAMER 407-PVP K30 INCLUSION COMPLEXES

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

Journal of Chemical and Pharmaceutical Research, 2018, 10(5): Research Article

Chemate and Chowdary, IJPSR, 2012; Vol. 3(7): ISSN:

Tablet Dissolution Testing

Experiences with USP Apparatus 4 Calibration

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

Development and Validation of a New Uv Method for the Analysis of Rebamipide

Dissolution Profiles of Diclofenac Potassium Tablets from the Argentinean Market

DEVELOPMENT OF UV SPECTROPHOTOMETRIC METHOD FOR THE ESTIMATION OF EZETIMIBE FROM TABLET FORMULATION

EFFECT OF STARCH HYDROLYSATES IN THE PROCESS OF DISSOLUTION OF SOLIDS

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

Preparation and Characterization of Candesartan Cilexetil Solid Lipid Nanoparticulate Capsules

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

Biowaiver for Immediate Release Solid Oral Dosage Form: A General Overview

Gastric, intestinal and colonic absorption of metoprolol in

Determination of bioavailability

Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

SPS Pharma: Who we are?

J Pharm Sci Bioscientific Res (4): ISSN NO

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

Telmisartan and Hydrochlorothiazide Tablets. Type of Posting. Revision Bulletin Posting Date. 26 Jan 2018 Official Date

International Journal of Medicine and Pharmaceutical Research

Development and Validation of a UV-Spectrophotometric Method for Quantification of Atorvastatin in Tablets

STUDY DESCRIBING THE FORMULATION AND THE RELEASE OF SOME ACTIVE PHARMACEUTICAL INGREDIENTS FROM HPMC HYDROPHILIC MATRIX TABLETS.

DEVELOPMENT AND EVALUATION OF A DIRECTLY COMPRESSIBLE CO PROCESSED MULTIFUNCTION SUSTAINED RELEASE AGENT FOR TABLETS

ENHANCEMENT OF SOLUBILITY, DISSOLUTION RATE AND BIOAVAILABILITY OF RITONAVIR BY CYCLODEXTRINS AND SOLUTOL HS15 - A FACTORIAL STUDY

FORMULATION RELEASE STUDY OF SOME IMPORTANT DRUGS FROM SUPPOSITORY

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS

Diabetes mellitus (DM) presents as a chronic disease

Formulation and Evaluation

J.Ayyappan et al, /J. Pharm. Sci. & Res. Vol.2 (7), 2010,

FABRICATION AND EVALUATION OF GLIMEPIRIDE CORDIA DICHOTOMA G.FORST FRUIT MUCILAGE SUSTAINED RELEASE MATRIX TABLETS

A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE

Biowaiver and Dissolution Profile Comparison

Volume 1(3) May-June 2013 Page 351

World Journal of Pharmaceutical Research

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or

Biopharmaceutics. Lec: 4

Advances in Prediction of Food Effects

International Journal of Drug Research and Technology

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

Biochemical Techniques 06 Salt Fractionation of Proteins. Biochemistry

Diltiazem Hydrochloride Extended-Release Capsules. Type of Posting Posting Date Official Date

Challenges with Dissolution Testing and Quality Assessment for Commercial Feverfew Products

FORMULATION AND EVALUATION OF ETORICOXIB TABLETS EMPLOYING CYCLODEXTRIN- POLOXAMER PVPK30 INCLUSION COMPLEXES

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

Helmut Schütz. Training on Bioequivalence Kaunas, 5 6 December

DEVELOPMENT AND EVALUATION OF ORAL RECONSTITUTABLE SYSTEMS OF CEPHALEXIN

L. Sriphong, A. Chaidedgumjorn, and K. Chaisuroj

Transcription:

FARMACIA, 2011, Vol. 59, 6 853 THE LACK OF BIOLOGICAL RELEVANCE OF THE OFFICIAL IN VITRO DISSOLUTION METHODOLOGY FOR THE IMMEDIATE RELEASE SOLID ORAL DOSAGE FORMS OF KETOCONAZOLE MITU MIRELA ADRIANA 1, RĂDULESCU FLAVIAN ŞTEFAN 2*, HÎRJĂU MIRCEA 1, LUPULEASA DUMITRU 1, DUMITRESCU ION- BOGDAN 3, MIRON DALIA SIMONA 3 University of Medicine and Pharmacy Carol Davila Bucharest, Faculty of Pharmacy, 6 th Traian Vuia street, 020956, Bucharest, Romania. 1 Department of Pharmaceutical Technology and Biopharmaceutics, 2 Department of Drug Industry and Pharmaceutical Biotechnologies, 3 Department of Pharmaceutical Physics and Informatics *corresponding author: flavian_stefan@yahoo.com Abstract The paper presents the effect of drastic ph variations during in vitro drug release tests on the dissolution profiles of ketoconazole reference immediate release oral solid dosage form. The acidic media induced a rapid and almost complete dissolution of ketoconazole, while the ph change determined an accelerated and continuous precipitation process, almost not dependent on the stirring rate. The results indicate that for generic drug products containing lipophilic weak bases, a rapid dissolution compared to the reference product could explain the reduced biopharmaceutical performances. Rezumat Lucrarea prezintă efectele variaţiilor drastice de ph induse pe durata testelor de cedare in vitro asupra profilelor de dizolvare ale ketoconazolului din forma farmaceutică solidă orală de referinţă. Mediu acid a indus o dizolvare rapidă şi aproape completă a ketoconazolului, iar schimbarea de ph a determinat un proces de precipitare accelerată şi continuă, aproape independentă de viteza de agitare. Rezultatele indică faptul că pentru produsele generice conţinând compuşii slab bazici lipofili, dizolvarea rapidă comparativ cu produsul referinţă poate explica performanţele biofarmaceutice reduse. Keywords: ketoconazole, tablets, dissolution test, media change. Introduction The development of generic solid oral dosage forms containing antifungal azoles with immediate release profiles frequently generates lower in vivo performance, compared to the reference product. This experimental fact is explained by the acido-basic properties of the drug molecule, especially the weak base properties of ketoconazole [1].

854 FARMACIA, 2011, Vol. 59, 6 The dissolution tests performed for formulation screening during the development phase of a generic drug product use a medium that assures the accurate solubility of ketoconazole (0.1N hydrochloric acid solution, ph=1.2), without considering the influence of the typical gastro-intestinal ph gradient on the solubility [2]. This gradient is correlated with the generation of oversaturated solution in some instances. The low value of the solubility at the site of absorption (intestinal segment), although associated with a fast dissolution in the gastric environment, induces a reduced bioavailability and in vitro in vivo non-correlations [3]. The current paper evaluated the impact of ph variation on the dissolution profile of ketoconazole from immediate release oral solid dosage forms. Also, the results generated according to two available dissolution monographs were compared (United States Pharmacopeia 30 National Formulary 25 (USP30-NF25, [4]) recommended procedure and a test with media change, designed for the evaluation of modified release oral drug products). The evaluation of the results was performed based on the physico-chemical properties of ketoconazole, but also on the physiological parameters with considerable influence on its biopharmaceutical profile (ph, motility etc.) [5]. Materials and Methods Two sets of in vitro dissolution studies were conducted using two USP 2 dissolution apparatus: Vankel 7000, Vankel Technology Group, USA, and Esadissolver 3, Advanced Products SRL, Italy. The first test was performed on six units of drug product (Nizoral TM tablets, SC Terapia SA, in collaboration with Janssen Pharmaceutica N.V. Bersee, batch no. 02050143). The dissolution media was composed of 900mL solution of hydrochloric acid 0.1N (ph=1.2), according to the USP30-NF25 [4] recommendations. Samples of 1.0 ml were collected at 5, 10, 15, 20, 30, 45 and 60 minutes after the debut of the test. The second experimental procedure represented an adaption of a typical, modified release drug product test recommendation: the initial use of an acidic dissolution media [4] (750 ml solution of hydrochloric acid 0.1N (ph=1.2), followed by a rapid ph change induced by adding 250 ml of 2M trisodium phosphate solution. The final ph of the media was 7.2, with a concentration of the buffer system of 50 mm. Five domains of agitation rate were implemented (50, 55, 60, 65 and 70 rpm), with probes of 1.0 ml sampled at 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105 and 120 min. These tests were performed on three units of drug product, at 37 C.

FARMACIA, 2011, Vol. 59, 6 855 The dissolution media degassed by filtration, using cellulose acetate filters (46 mm diameter, 0.45 µm pore diameter, with an Agilent Technologies filtration system), the filtrate being maintained at 41 C under 900 mbar vacuum. The ph of the dissolution media was controlled using a Combo HI 98130, Hanna Instruments ph-meter, before distribution into the dissolution vessels. The sampled probes were filtrated using canula filters immersed in the dissolution media (10 µm pore size). The quantitative evaluation of dissolved ketoconazole amounts was performed using a spectrophotometric method (at 221 nm), after adequate dilution with the corresponding media (either acidic or phosphate buffer) and further interpolation on the calibration curves (using a double fascicle, Jasco V-530 model spectrophotometer). All the other reagents and the analytical standard of ketoconazole were purchased from Sigma Aldrich. The purified water was generated by a SGW Ultraclear UV Plus TM system. Results and Discussion Two types of dissolution methodologies were implemented for ketoconazole immediate release oral solid dosage forms. The first test confirmed the rapid and almost complete dissolution of the active pharmaceutical ingredient in the compendial recommended acidic media (figure 1). This release pattern is typical for the compounds with weak base characteristics, determining an accurate solubility within the gastric environment. 120 100 % Dissolved 80 60 40 Mean 75 rpm 20 0 0 10 20 30 40 50 60 Time (min) Figure 1 Mean dissolution profile of ketoconazole tablets at 75 rpm in acidic media (N=6)

856 FARMACIA, 2011, Vol. 59, 6 The second set of tests represented an adaption of the compendial monograph for evaluation of the media change on the in vitro drug release profile of the modified release oral solid dosage forms. The final ph of the dissolution media, induced by adding the 50 mm trisodium phosphate 2 M solution, corresponded to the typical values of the physiological environment, that is the jejunum-ileum segment, the major site of absorption by passive diffusion processes, with or without the involvement of the active transport systems. The five different values of agitation rate, in the interval of 50 to 70 rpm, in steps of 5 rpm, intended to investigate, within the ph dependence of the solubility profile, the influence of the hydrodynamics on the amount dissolved. This last parameter could be associated to the inter-individual variability of the gastro-intestinal motility. During the first 30 minutes (corresponding to the half-life of the gastric evacuation rate) the amount of ketoconazole dissolved was directly correlated to the agitation rate, the differences being considered as not significant (the profiles were similar, with 95.26% dose dissolved for 50 rpm, and 98.11% for 70 rpm, respectively) (figure 2). 120 100 % Dissolved 80 60 40 Mean 50 rpm Mean 55 rpm Mean 60 rpm Mean 65 rpm Mean 70 rpm 20 0 0 30 60 90 120 Time (min) Figure 2 Mean dissolution profiles of ketoconazole tablets at 50, 55, 60, 65 and 70 rpm (media change after 30 minutes; N=3)

FARMACIA, 2011, Vol. 59, 6 857 The reported differences between the two types of in vitro drug release tests at 30 minutes (e.g. the higher amount dissolved of ketoconazole at 60, 65 and 70 rpm in 750 ml, compared to the 75 rpm in 900 ml acidic environment, with values of similarity factor lower than 50) could be explained partially by the assumed, existing differences in hydrodynamic parameters induced by the volume of dissolution media. Table I The influence of dissolution test conditions on the similarity factor, f2 [5] a) time interval: 0-30 minutes. f2 75 rpm 50 rpm 55 rpm 60 rpm 65 rpm 70 rpm 75 rpm 100 69.27 54.85 49.6 44.03 41.55 50 rpm 69.27 100 64.39 57.44 49.98 46.24 55 rpm 54.85 64.39 100 80.04 62.25 57.23 60 rpm 49.6 57.44 80.04 100 73.29 64.78 65 rpm 44.03 49.98 62.25 73.29 100 79.99 70 rpm 41.55 46.24 57.23 64.78 79.99 100 b) time interval: 0-120 minutes. f2 50 rpm 55 rpm 60 rpm 65 rpm 70 rpm 50 rpm 100 71.92 64.05 57.42 53.3 55 rpm 71.92 100 82.2 69.31 63.28 60 rpm 64.05 82.2 100 80.98 71.94 65 rpm 57.42 69.31 80.98 100 84.47 70 rpm 53.3 63.28 71.94 84.47 100 The instant variation of ph value generated an intense precipitation of ketoconazole, process that continued during the next 90 minutes. It is to be mentioned the impact on the remaining amount dissolved of ketoconazole, inversely correlated with the quantity released at the moment when the ph change was induced (4.61% for 50 rpm and 3.39% for 70 rpm) (figure 3).

858 FARMACIA, 2011, Vol. 59, 6 100 80 95,26 95,33 95,86 96,18 98,11 60 40 20 0 4,61 4,59 50 rpm 55 rpm 60 rpm 65 rpm 70 rpm 3,89 % dissolved in 30 min (ph=1.2) 3,86 % dissolved in 120 min (ph=7.2) Figure 3 The variation of the ketoconazole amount dissolved at 30 and 120 minutes 3,39 The similarity of the precipitation profiles could be explained, but the final volume of the in vitro drug release media has no physiological correspondence [5,6]. At the gut level, the presence of small volumes (approximately 100-200 ml of intestinal fluid), with regional distribution, could drive to a more intense precipitation, even in the presence of endogenous tensioactive agents, such as bile acids and salts [7]. Conclusions For basic drug substances, administered as immediate release solid oral dosage forms, a fast dissolution within the gastric environment could be followed by an intense precipitation in the gut lumen, generating a slow, solubility limited absorption process. It is the paradox of inferior bioavailability reported by the drug manufacturers when the generic formulation releases faster compared to the reference one, since compendial dissolution test results are assumed to display also a biological relevance. The currently recommended drug dissolution tests are intended for batch quality control purposes (within Scale Up Post Approval Changes framework), in order to reveal the impact of various formulation and/or process changes. One of the approaches available in order to avoid the nonbiosimilarity of drug products containing basic active pharmaceutical

FARMACIA, 2011, Vol. 59, 6 859 ingredients could be a different acceptance criteria for the similarity factor, while requesting similar release kinetics and a lower mean difference (<10%). Acknowledgements This paper was partially supported by the Sectoral Operational Programme Human Resources Development, financed from the European Social Fund and by the Romanian Government under the contract number POSDRU/89/1.5/S/64153. References 1. Mircioiu C, Voicu V, Miron D, Mircioiu I: Non-standard correlations: in vitro in vivo correlations for immediate release products: comparison of different bioequivalence experiments. Basic Clin Pharmacol Toxicol. 2005;96(3):265-7. 2. Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12(3):397-406. 3. Mircioiu C, Mircioiu I, Voicu V, Miron D. Dissolution-bioequivalence non-correlations. Basic Clin Pharmacol Toxicol. 2005;96(3):262-4. 4. United States Pharmacopoeia 30 National Formulary 25, 2006. 5. Klein S, Dressman JB, Reppas C. In vitro methods to predict food effects. In: Amidon G, Lesko L, Midha K, Shah V, Hilfinger J. (eds.) International bioequivalence standards: A new era. TSRL Inc. 2006; Ann Harbor, USA. 6. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB., Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15:698-705. 7. Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants, Int J Pharm. 1989;6(7):612-8. Manuscript received: March 12 th 2011